CommercialCoverageMedium impact
Whole Exome and Whole Genome Sequencing for Diagnosis of Genetic Disorders (2.04.102)
Blue Shield of California·CA · Genetics, Pediatrics, Critical Care +1 more·Genetic Testing
Effective date
Apr 1, 2026
We identified it
Dec 1, 2025
Summary
Blue Shield of California updated their policy for whole exome and whole genome sequencing, establishing specific medical necessity criteria for genetic testing in unexplained congenital/neurodevelopmental disorders and critically ill infants. The policy clarifies when these tests are considered medically necessary versus investigational, with different requirements for standard versus rapid sequencing.
Action Required
Before April 1, 2026: Billing team must review current genetic testing authorization processes and update prior authorization workflows to align with new medical necessity criteria. Ensure documentation requirements are met including genetic counseling, family history, phenotype description, and evidence that genetic etiology is most likely explanation. Update encounter forms to capture required clinical elements for whole exome/genome sequencing claims.